RBC Capital analyst Kennen MacKay reiterated a Sector Perform rating on Regeneron Pharma (NASDAQ: REGN) after the company announced an ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE